OCPNF:OTC-Olympus Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 16.71

Change

0.00 (0.00)%

Market Cap

USD 21.42B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others segments. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopy systems, surgical microscopes, endoscope reprocessors, and maintenance services. The Therapeutic Solutions Business segment provides urology, gynecology, respiratory, ear, nose, and throat products; GI endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials, such as synthetic bone filler, and orthopedic equipment. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

-0.58 (-0.50%)

USD 109.05B
ESLOF EssilorLuxottica Société ano..

-1.38 (-0.60%)

USD 107.93B
HOCPF HOYA Corporation

N/A

USD 48.46B
HOCPY Hoya Corp

+2.25 (+1.71%)

USD 45.95B
CLPBF Coloplast A/S

N/A

USD 29.48B
CLPBY Coloplast A

-0.28 (-2.14%)

USD 29.48B
TRUMF Terumo Corporation

+0.11 (+0.60%)

USD 28.34B
SAUHF Straumann Holding AG

-3.14 (-2.38%)

USD 24.34B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.59B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 20.59B

ETFs Containing OCPNF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.48% 73% C 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.48% 73% C 64% D
Trailing 12 Months  
Capital Gain 26.26% 69% C- 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.26% 69% C- 66% D+
Trailing 5 Years  
Capital Gain 25.45% 79% B- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.45% 79% B- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 1.99% 40% F 42% F
Dividend Return 2.25% 39% F 38% F
Total Return 0.26% 21% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 22.50% 87% B+ 83% B
Risk Adjusted Return 9.98% 45% F 43% F
Market Capitalization 21.42B 85% B 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.